Medicenna Therapeutics Corp. announced that Mann Muhsin has resigned as Chief Medical Officer of the company to assume a position closer to home. Martin Bexon who has managed many aspects of Medicenna's clinical programs since 2016, will serve as Acting Chief Medical Officer in addition to his current role as the Medical Monitor for the Phase 1/2 ABILITY study.

Medicenna also announced the appointment of industry veterans to its Development Advisory Committee. Dr. Martin Bexon has worked as a strategic adviser, study medical expert, and medical monitor in a number of oncology programs in both solid tumors and hematological malignancies. While at CSL Behring (Bern, Switzerland), he led multiple global clinical studies across a range of indications.

At Hoffman-La Roche (U.K. and Switzerland), Martin designed and executed multiple global clinical trials enrolling more than 10,000 subjects to support product commercialization. Mr. Paul Smith, Dr. Bruce Pearce and Dr. Peter Lloyd, who have been instrumental in supporting MDNA11's pre-clinical safety, PK/PD studies, international regulatory filings and designing the ABILITY study. Paul Smith brings 25 years of global regulatory experience with a focus on oncology.

He has held positions of increasing responsibilities during his 20-year tenure at Amgen before joining Tusk Therapeutics (an immuno-oncology company targeting the IL-2 CD25 receptor) as VP of Regulatory Affairs until its acquisition by Roche and more recently has been guiding Medicenna's global regulatory submissions and strategy for MDNA11. Dr. Peter Lloyd, PhD, has more than 25 years of drug development experience, mostly at Novartis. His expertise spans PK/PD models, immunogenicity assessment and exposure response relationships with both small molecule and biologics.

He was formerly the Head of DM/PK Biologics at Novartis and has been the key contributor to MDNA11's PK studies and PK modeling.